docetaxel anhydrous has been researched along with pomolic acid in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (pomolic acid) | Trials (pomolic acid) | Recent Studies (post-2010) (pomolic acid) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 53 | 0 | 31 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | pomolic acid (IC50) |
|---|---|---|---|
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | 3.9 | |
| Sentrin-specific protease 1 | Homo sapiens (human) | 5.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gattass, CR; Martins, CA; Rocha, GDG; Takiya, CM | 1 |
1 other study(ies) available for docetaxel anhydrous and pomolic acid
| Article | Year |
|---|---|
Pomolic acid exhibits anticancer potential against a docetaxel‑resistant PC3 prostate cell line.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Male; Multidrug Resistance-Associated Proteins; Oleanolic Acid; Prostatic Neoplasms | 2019 |